Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 178-186

  Francois, Asvi A ^a   Nishida, Clinton R ^b   Ortiz De Montellano, Paul R ^b   Phillips, Ian R ^c   Shephard, Elizabeth A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CYANAMIDE; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 2.1; DRUG METABOLITE; ETHIONAMIDE; QUERCETIN; SULFENIC ACID DERIVATIVE; SULFINIC ACID DERIVATIVE; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTITUBERCULAR AGENTS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHIONAMIDE; HUMANS; MASS SPECTROMETRY; OXIDATION-REDUCTION; OXYGEN; OXYGENASES; SPECTROPHOTOMETRY, ULTRAVIOLET; THIOACETAZONE;

CORYNEBACTERINEAE; MAMMALIA;

EID: 58149458151     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024158     Document Type: Article

References (40)

1. Alahari A, Trivelli X, Guérardel Y, Dover LG, Besra GS, Sacchettini JC, Reynolds RC, Coxon GD, and Kremer L (2007) Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS ONE 2:e1343.
2. Baulard AR, Betts JC, Engohang-Ndong J, Quan S, McAdam RA, Brennan PJ, Locht C, and Besra GS (2000) Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 275:28326-28331.
3. Brown P (1992) Cheap TB drug 'too dangerous' for Africa. New Sci 135:5.
4. Cashman JR and Zhang J (2006) Human flavin-containing monooxygenases. Anna Rev Pharmacol Toxicol 46:65-100.
5. DeBarber AE, Mdluli K, Bosnian M, Bekker LG, and Barry CE 3rd (2000) Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 97:9677-9682.
6. Decker CJ and Doerge DR (1992) Covalent binding of 14C- and 35S-labeled thiocarbamides in rat hepatic microsomes. Biochem Pharmacol 43:881-888.
7. Dixit A and Roche TE (1984) Spectrophotometric assay of the flavin-containing monooxygenase and changes in its activity in female mouse liver with nutritional and diurnal conditions. Arch Biochem Biophys 233:50-63.
8. Dolphin C, Shephard EA, Povey S, Palmer CN, Ziegler DM, Ayesh R, Smith RL, and Phillips LR (1991) Cloning, primary sequence, and chromosomal mapping of a human flavincontaining monooxygenase (FMO1). J Biol Chem 266:12379-12385.
9. Dolphin CT, Beckett DJ, Janmohamed A, Cullingford TE, Smith RL, Shephard EA, and Phillips LR (1998) The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a Truncated, nonfunctional protein. J Biol Chem 273:30599-30607.
10. Dolphin CT, Cullingford TE, Shephard EA, Smith RL, and Phillips IR (1996) Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Eur J Biochem 235:683-689.
11. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (1997) Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet 17:491-494.
12. Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, Reynolds RC, Besra GS, and Kremer L (2007) EthA, a common activator of thiocarbamide-contain ing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother 51:1055-1063.
13. Henderson MC, Krueger SK, Stevens JF, and Williams DE (2004) Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chem Res Toxicol 17:633-640.
14. Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-130.
15. Hisamuddin IM, Wehbi MA, Schtnotzer B, Easley KA, Hylind LM, Giardiello FM, and Yang VW (2005) Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 14:2366-2369.
16. Ipuge YA, Rieder HL, and Enarson DA (1995) Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania. Lancet 346:657-660.
17. Janmohamed A, Dolphin CT, Phillips IR, and Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777-786.
18. Janmohamed A, Thaunsukon P, Shephard EA, and Phillips R (2006) Expression of recombinant flavin-containing monooxygenases in a baculovirus/insect cell system, in Cytochrome P450 Protocols (Phillips IR and Shephard EA eds) ed 2, pp 307-319,
19. Humana Press Totowa, NJ. Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, and Hines RN (2005) Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol Pharmacol 68:383-392.
20. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236-243.
21. Krieter PA, Ziegler DM, Hill KE, and Burk RF (1984) Increased biliary GSSG efflux from rat livers perfused with thiocarbamide substrates for the flavin-containing monooxygenases. Mol Pharmacol 26:122-127.
22. Krueger SK, Martin SR, Yueh MF, Pereira CB, and Williams DE (2002) Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein. Drug Metab Dispos 30:34-41.
23. Krueger SK and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357-387.
24. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 31:854-860.
25. Lawton MP, Kronbach T, Johnson EF, and Philpot RM (1991) Properties of expressed and native flavin-containing monooxygenases: evidence of multiple forms in rabbit liver and lung. Mol Pharmacol 40:692-698.
26. Onderwater RC, Commandeur JN, and Vermeulen NP (2004) Comparative cytotoxicity of N-substituted N′-(4-imidazole-ethyl)thiourea in precision-cut rat liver slices. Toxicology 197: 81-91.
27. Onderwater RC, Rettie AE, Commandeur JN, and Vermeulen NP (2006) Bioactivation of N-substituted N′-(4-imidazole-ethyl)thioureas by human FMO1 and FMO3. Xenobiotica 36: 645-657.
28. Peloquin CA (1993) Pharmacology of the antimycobacterial drugs. Med Clin North Am 77: 1253-1262.
29. Phillips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, McCombie RR, Smith RL, and Shephard EA (1995) The molecular biology of the flavin-containing monooxygenases of man. Chem Biol Interact 96:17-32.
30. Phillips IR, Francois AA, and Shephard EA (2007) The flavin-containing monooxygenases (FMOs): Genetic variation and its consequences for the metabolism of therapeutic drugs. Current Pharmacogenomics 5:292-313.
31. Phillips IR and Shephard EA (2008) Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol Sci 29:294-301.
32. Qian L and Ortiz de Montellano PR (2006) Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem Res Toxicol 19:443-449.
33. Smith PB and Crespi C (2002) Thiourea toxicity in mouse C3H/10T1/2 cells expressing human flavin-dependent monooxygenase 3. Biochem Pharmacol 63:1941-1948.
34. StörmerE, Roots I, and Brockmöller J (2000) Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553-561.
35. Teklu B (1976) Gastrointestinal toxicity of thiacetazone. Ethiop Med J 14:17-22.
36. Vannelli TA, Dykman A, and Ortiz de Montellano PR (2002) The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 277:12824-12829.
37. *1 is at high frequency throughout Sub-Saharan Africa. Pharmacogenet Genomics 18:877-886.
38. Whetstine JR, Yueh MF, McCarver DG, Williams DE, Park CS, Kang JH, Cha YN, Dolphin CT, Shephard EA, Phillips IR, et al. (2000) Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168:216-224.
39. Yeung CK, Lang DH, Thummel KE, and Rettie AE (2000) Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drag Metab Dispos 28:1107-1111.
40. Ziegler DM (2002) An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab Rev 34:503-511.